Gilead to sell cheaper version of hepatitis C drugs that sparked debate

Gilead Sciences will sell cheaper versions of its blockbuster hepatitis C drugs, the original versions of which sparked widespread debate about pharmaceutical costs when they were introduced at a price of more than $1,000 a pill.
The new, cheaper versions of Gilead’s Epclusa and Harvoni will cost $24,000 for a course of treatment, the Foster City company said Monday. When Harvoni came on the market in 2014, Gilead set a list price of $94,500. Epclusa was approved for sale in 2016, with a price of $74,760.
Gilead, like almost all pharmaceutical companies, already offers discounts on the sticker price of its treatments, but those discounts aren’t always passed on to patients.